Stockscreener 앱 받기
62.38
1.35%
0.83
시간 외 거래:
60.87
-1.51
-2.42%
Arrowhead Pharmaceuticals Inc 주식(ARWR)의 최신 뉴스
Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million - AOL.com
Equities Analysts Issue Forecasts for ARWR Q2 Earnings - MarketBeat
Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Strong Earnings Are Of Good Quality - simplywall.st
The Strong Earnings Posted By Arrowhead Pharmaceuticals (NASDAQ:ARWR) Are A Good Indication Of The Strength Of The Business - 富途牛牛
Understanding the Setup: (ARWR) and Scalable Risk - Stock Traders Daily
ARWR: Strong Start for REDEMPLO Commercialization - Smartkarma
ARWR: Strong Start for REDEMPLO Commercialization… - Yahoo Finance
Arrowhead Pharmaceuticals' (ARWR) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Arrowhead Pharma (ARWR) Receives Buy Rating from HC Wainwright | - GuruFocus
Breaking Down Arrowhead Pharma: 18 Analysts Share Their Views - Benzinga
Goldman Sachs Maintains Neutral on ARWR Arrowhead Pharmaceuticals Feb 2026 - Meyka
Arrowhead Pharmaceuticals (ARWR) Stock Analysis: A 30% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Arrowhead Pharmaceuticals stock swings as S&P MidCap 400 move lands and Goldman flags 2026 catalysts (ARWR) - TechStock²
Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ Novel Treatments | DelveInsight - GlobeNewswire Inc.
Arrowhead Pharma stock outlook: Goldman Sachs sees 2026 catalysts ahead - Investing.com
Arrowhead Pharmaceuticals, Inc.(NasdaqGS: ARWR) added to S&P 400Biotechnology - marketscreener.com
Top Pharmaceutical Stocks To Follow TodayFebruary 8th - MarketBeat
Arrowhead Pharmaceuticals Earnings Call Flags Pivotal 2026 - TipRanks
Best Pharmaceutical Stocks To Add to Your WatchlistFebruary 7th - MarketBeat
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Strong 1 Year Shareholder Return - Yahoo Finance
Principal Financial Group Inc. Buys 157,035 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals (ARWR) Q1 Profit Challenges Bearish Narratives On Earnings Quality - Sahm
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2026 Earnings Call Transcript - Insider Monkey
Arrowhead gains approval of Redemplo in China for high triglycerides - MSN
More Rivalry With Ionis In A Potentially ‘Transformational’ Year For Arrowhead - Citeline News & Insights
Arrowhead’s RNAi Platform Shifts Toward Commercialization And Broader Partnerships - Sahm
Arrowhead Pharmaceuticals (ARWR) Reports Strong Q1 2026 Performa - GuruFocus
Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results - BioSpace
Decoding Arrowhead Pharmaceuticals Inc (ARWR): A Strategic SWOT Insight - GuruFocus
Earnings Call Summary | Arrowhead Pharmaceuticals(ARWR.US) Q1 2026 Earnings Conference - 富途牛牛
Arrowhead Pharmaceuticals Inc (ARWR) Q1 2026 Earnings Call Highl - GuruFocus
Arrowhead Pharmaceuticals Inc (ARWR) Q1 2026 Earnings Call Highlights: Strong Financial ... By GuruFocus - Investing.com Canada
Arrowhead Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat
Earnings call transcript: Arrowhead Pharmaceuticals beats Q1 2026 EPS forecast - Investing.com India
Arrowhead (ARWR) Q1 2026 Earnings Call Transcript - The Globe and Mail
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Issues Quarterly Earnings Results - MarketBeat
Earnings Flash (ARWR) Arrowhead Pharmaceuticals, Inc. Reports Q1 Revenue $264.0M, vs. FactSet Est of $213.9M - marketscreener.com
Arrowhead (ARWR) Set to Join S&P 400 Index - GuruFocus
Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600 - Yahoo Finance
Is Arrowhead Pharmaceuticals (ARWR) Pricing Reflect Recent RNAi Progress And Strong Share Price Gains? - Sahm
Trading Action: Is Arrowhead Pharmaceuticals Inc gaining market share2025 Institutional Moves & Low Risk Entry Point Tips - baoquankhu1.vn
Why Arrowhead Pharmaceuticals (ARWR) Is Up 7.8% After Launching Its First Dual-Gene RNAi Trial - Yahoo Finance
Arrowhead Pharmaceuticals (ARWR) Valuation After First Human Dosing Of Dual Gene RNAi Therapy For Mixed Hyperlipidemia - Sahm
The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following First Dual-Gene RNAi Cardio Trial Initiation - Sahm
The Technical Signals Behind (ARWR) That Institutions Follow - Stock Traders Daily
Arrowhead Pharmaceuticals at Risk: Potential Generic Competition Threatens REDEMPLO’s Market Exclusivity - MSN
Arrowhead Pharmaceuticals, Inc. $ARWR is Privium Fund Management B.V.'s 9th Largest Position - MarketBeat
Arrowhead gains, Agios drops as drug developers end 2025 up 34% - BioWorld MedTech
Can Arrowhead Pharmaceuticals Inc. weather a recessionJuly 2025 Catalysts & Accurate Entry/Exit Alerts - Mfd.ru
Is Arrowhead Pharmaceuticals Inc. stock a buy or sellLayoff News & Precise Swing Trade Entry Alerts - mfd.ru
How cyclical is Arrowhead Pharmaceuticals Inc.’s revenue stream2025 Valuation Update & Scalable Portfolio Growth Ideas - Mfd.ru
Arrowhead Pharmaceuticals (ARWR) to Release Quarterly Earnings on Thursday - MarketBeat
Sarepta sells Arrowhead stock, activates $100M milestone payment - MSN
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia - BioSpace
Arrowhead Pharma stock holds steady as Morgan Stanley maintains rating By Investing.com - Investing.com Canada
Arrowhead Pharmaceuticals (ARWR) Stock Analysis: Navigating Biotech Innovation with a 22.59% Upside Potential - DirectorsTalk Interviews
Arrowhead (ARWR) Advances with New Atherosclerosis Treatment Tri - GuruFocus
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PAthe First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia - marketscreener.com
Arrowhead begins Phase 1/2a trial of first dual-target RNAi therapy By Investing.com - Investing.com South Africa
Arrowhead begins Phase 1/2a trial of first dual-target RNAi therapy - Investing.com
160,985 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Acquired by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Arrowhead Pharmaceuticals (ARWR) Is Up 5.0% After China Approves Redemplo Commercialisation With Sanofi - Sahm
1.24%
0.19%
자본화:
|
볼륨(24시간):